COMMUNIQUÉS West-GlobeNewswire

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
06/05/2025
A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke [...]
DrEO Clinic Named Best Hair Transplant Clinic in Mexico for 2025, Leading the Way in Affordable Medical Tourism
05/05/2025
Mexico City, Mexico, May 05, 2025 (GLOBE NEWSWIRE) -- DrEO Clinic has been recognized as the best hair transplant clinic in Mexico for 2025, reinforcing its position at the forefront of hair restoration excellence. The [...]
Evolved Extraction Solutions Announces Strategic Expansion in U.S. Market Amid Industry Shakeup
05/05/2025
Following the closure of ExtractionTek Stainless and Precision Extraction, Evolved emerges as the financially strong, forward-focused partner—with cross-compatible technology, new U.S. leadership, and end-to-end [...]
Solésence Reports Record First Quarter 2025 Financial Results
05/05/2025
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and [...]
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
05/05/2025
Phase 2 study fully enrolled; data expected in 2H 2025 HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab [...]
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
05/05/2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it [...]
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
05/05/2025
– $20.0 million in Revuforj ® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted [...]
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
05/05/2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May [...]
Xenon to Report Q1 2025 Financial Results on May 12, 2025
05/05/2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook
05/05/2025
Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter [...]
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
05/05/2025
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the [...]
uniQure to Announce First Quarter 2025 Financial Results
05/05/2025
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy [...]
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
05/05/2025
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile [...]
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
05/05/2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
05/05/2025
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients [...]
FibroGen to Report First Quarter 2025 Financial Results
05/05/2025
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on [...]
Castle Biosciences to Acquire Previse
05/05/2025
Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, [...]
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
05/05/2025
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the [...]
Context Therapeutics Announces Chief Medical Officer Transition
05/05/2025
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical [...]

Pages